$FATE Fate Therapeutics is Initiated by Wells Fargo to Outperform , according to the research report released to the investors. The shares recommendation by the Brokerage Firm was released on Dec-4-2015.
Many analysts have commented on the company rating. Raymond James initiates coverage on Fate Therapeutics, Inc. (NASDAQ:FATE) In a research note issued to the investors, the brokerage major announces a price-target of $8 per share.The shares have been rated Outperform. The rating by the firm was issued on October 6, 2015.
The company shares have rallied 8.27% from its 1 Year high price. On May 6, 2015, the shares registered one year high at $8.78 and the one year low was seen on Oct 22, 2015. The 50-Day Moving Average price is $4.29 and the 200 Day Moving Average price is recorded at $5.97.
Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) ended Tuesday session in red amid volatile trading. The shares closed down 0.01 points or 0.24% at $4.18 with 80,729 shares getting traded. Post opening the session at $4.21, the shares hit an intraday low of $4.1 and an intraday high of $4.235 and the price vacillated in this range throughout the day. The company has a market cap of $120 million and the number of outstanding shares have been calculated to be 28,716,570 shares. The 52-week high of Fate Therapeutics, Inc. (NASDAQ:FATE) is $8.781 and the 52-week low is $3.1235.
Fate Therapeutics, Inc. (NASDAQ:FATE): 4 Brokerage firm Analysts have agreed with the mean estimate for the short term price target of $9.75 in Fate Therapeutics, Inc. (NASDAQ:FATE). However, the stock price could fluctuate by $ 1.26 from the estimate as it is suggested by the standard deviation reading. The higher estimate has been put at $11 price target with the lower price estimate is calculated at $8.
Currently the company Insiders own 17.43% of Fate Therapeutics, Inc. shares according to the proxy statements. Institutional Investors own 63.91% of Fate Therapeutics, Inc. shares.
Fate Therapeutics, Inc, is a clinical-stage biopharmaceutical company engaged in the discovery and development of pharmacologic modulators of adult stem cells to treat orphan diseases, including hematologic malignancies, lysosomal storage disorders and muscular dystrophies. Its approaches utilize pharmacologic modalities, including small molecules and therapeutic proteins, and biological mechanisms to enhance the therapeutic potential of adult stem cells.BLOG COMMENTS POWERED BY DISQUS